Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 1/20 | 0.59 |
| ▸ | GRK5 | P34947 | 1/20 | 0.59 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.59 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.59 |
| ▸ | CA12 | O43570 | 10/20 | 0.47 |
| ▸ | CA2 | P00918 | 10/20 | 0.47 |
| ▸ | CA9 | Q16790 | 10/20 | 0.47 |
| ▸ | CA1 | P00915 | 8/20 | 0.47 |
| ▸ | CA4 | P22748 | 7/20 | 0.47 |
| ▸ | CA7 | P43166 | 7/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | CA6 | P23280 | 1/20 | 0.47 |
| ▸ | CA5A | P35218 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7280710 | 0.88 | RET (0.54) | RETGRK5TYRO3DYRK1BCA12 | |
| SCHEMBL18790754 | 0.85 | RET (0.51) | RETGRK5TYRO3DYRK1BCA12 | |
| SCHEMBL20646900 | 0.83 | RET (0.53) | RETGRK5TYRO3DYRK1BCA12 | |
| SCHEMBL18790752 | 0.80 | RET (0.53) | RETGRK5TYRO3DYRK1BCA12 | |
| SCHEMBL7023285 | 0.78 | RET (0.62) | RETGRK5TYRO3DYRK1BCA12 | |
| SCHEMBL18790753 | 0.78 | RET (0.50) | RETGRK5TYRO3DYRK1BCA12 | |
| SCHEMBL7281756 | 0.77 | RET (0.53) | RETGRK5TYRO3DYRK1BCA12 | |
| SCHEMBL18790756 | 0.77 | RET (0.49) | RETGRK5TYRO3DYRK1BCA12 | |
| SCHEMBL9407224 | 0.76 | RET (0.51) | RETGRK5TYRO3DYRK1BCA12 | |
| SCHEMBL7381362 | 0.74 | RET (0.62) | RETGRK5TYRO3DYRK1BCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018115-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | LOXO ONCOLOGY, INC. | 2024-01-18 | — | — | US | disclosed |
| EP-0550111-B1 | 2-Saccharinylmethyl heterocyclic carboxylates useful as proteolytic enzyme inhibitors and pharmaceutical compositions containing them | SANOFI SA (FR) | 1999-04-14 | — | — | EP | disclosed |
| US-5874432-A | Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof | SANOFI (FR) | 1999-02-23 | — | — | US | disclosed |
| US-5856349-A | 2-Saccharinylmethyl heterocyclic carboxylates useful as proteolytic enzyme inhibitors and compositions and method of use thereof | SANOFI (FR) | 1999-01-05 | — | — | US | disclosed |
| US-5783589-A | 2-saccharinylmethyl aryl and arloxy acetates useful as proteolytic enzyme inhibitors and compositions and method of use thereof | SANOFI (FR) | 1998-07-21 | — | — | US | disclosed |
| EP-0471756-B1 | SACCHARIN DERIVATIVES USEFUL AS PROTEOLYTIC ENZYME INHIBITORS AND PREPARATION THEREOF | SANOFI SA (FR) | 1997-10-29 | — | — | EP | disclosed |
| US-5652254-A | TREATMENT OF DEGENERATIVE DISEASES, RHEUMATOID ARTHRITIS, PSORIASIS, CYSTIC FIBROSIS | SANOFI, S.A. (FR) | 1997-07-29 | — | — | US | disclosed |
| US-5650422-A | TREATMENT OF EMPHYSEMA, ARTHRITIS OR PANCREATITIS | SANOFI (FR) | 1997-07-22 | — | — | US | disclosed |
| EP-0549073-B1 | Novel 2-saccharinylmethyl and 4,5,6,7-tetrahydro-2-saccharinylmethyl phosphates, phosphonates and phosphinates useful as proteolytic enzyme inhibitors and compositions and method of use thereof | SANOFI SA (FR) | 1997-03-26 | — | — | EP | disclosed |
| US-5597841-A | 2-saccharinylmethyl aryl carboxylates useful as proteolytic enzyme inhibitors and compositions and method of use thereof | STERLING WINTHROP, INC. (US) | 1997-01-28 | — | — | US | disclosed |
| EP-0550112-A1 | 2-Saccharinylmethyl aryl and aryloxy acetates useful as proteolytic enzyme inhibitors and pharmaceutical compositions contaning them | STERLING WINTHROP INC. (US) | 1993-07-07 | — | — | EP | disclosed |
| EP-0550111-A1 | 2-Saccharinylmethyl heterocyclic carboxylates useful as proteolytic enzyme inhibitors and pharmaceutical compositions containing them | STERLING WINTHROP INC. (US) | 1993-07-07 | — | — | EP | disclosed |
| EP-0549073-A1 | Novel 2-saccharinylmethyl and 4,5,6,7-tetrahydro-2-saccharinylmethyl phosphates, phosphonates and phosphinates useful as proteolytic enzyme inhibitors and compositions and method of use thereof | STERLING WINTHROP INC. (US) | 1993-06-30 | — | — | EP | disclosed |
| EP-0542372-A1 | 2-Substituted saccharin derivative proteolytic enzyme inhibitors | STERLING WINTHROP INC. (US) | 1993-05-19 | — | — | EP | disclosed |
| US-5187173-A | Degenerative diseases such as emphysema, rheumatoid arthritis, pancreatitis, cyctic fibrosis and skin disorders | STERLING WINTHROP INC. (US) | 1993-02-16 | — | — | US | disclosed |
| US-5128339-A | Emphysema, rheumatoid arthritis, pancreatitis | STERLING WINTHROP INC. (US) | 1992-07-07 | — | — | US | disclosed |
| EP-0483928-A1 | 2-Saccharinylmethyl aryl carboxylates useful as proteolytic enzyme inhibitors and compositions and method of use | STERLING WINTHROP INC. (US) | 1992-05-06 | — | — | EP | disclosed |
| EP-0471756-A4 | SACCHARIN DERIVATIVES USEFUL AS PROTEOLYTIC ENZYME INHIBITORS AND PREPARATION THEREOF | — | 1992-04-08 | — | — | EP | disclosed |
| EP-0471756-A1 | SACCHARIN DERIVATIVES USEFUL AS PROTEOLYTIC ENZYME INHIBITORS AND PREPARATION THEREOF. | STERLING WINTHROP INC (US) | 1992-02-26 | — | — | EP | disclosed |
| WO-1990013549-A1 | SACCHARIN DERIVATIVES USEFUL AS PROTEOLYTIC ENZYME INHIBITORS AND PREPARATION THEREOF | STERLING WINTHROP INC. (US) | 1990-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018115-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PIK3CA, PIK3R4, PIK3R5 | RET 193/4885GRK5 79/4885TYRO3 554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.